Orforglipron

In human trials

• See source wording

  by mouth · once daily

  A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or OverweightPHASE1 · NCT06440980

  “Doses were administered as follows: * Period 1: 1 mg (Capsule) * Period 2: Dose Level 2 (Tablet) * Period 3: Dose Level 1 (Tablet) * Period 4: Dose Level 3 (Tablet) * Period 5: 3 mg (Capsule) * Period 6: Dose Level 5 (Tablet) * Period 7: Dose Level 4 (Tablet) * Period 8: Dose Level 6 (Tablet) * Period 9: 6 mg (Capsule) * Period 10: Dose Level 8 (Tablet) * Period 11: Dose Level 7 (Tablet) * Period 12: Dose Level 9 (Tablet).”

• See source wording

  by mouth

  Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy DiscontinuationPHASE4 · NCT07729332

  “Phentermine 8 mg or 37.5 mg tablet.”

• See source wording

  by mouth · once daily

  A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise AlonePHASE3 · NCT05971940

  “3 mg Orforglipron.”

• See source wording

  by mouth · single dose

  A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy ParticipantsPHASE1 · NCT06704763

  “* Day 1: single dose of 1 mg orforglipron.”

• See source wording

  by mouth · once daily · for 12 weeks

  A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese ParticipantsPHASE1 · NCT06186622

  “Participants received single oral doses as follows:Day 1: 20 milligram(mg) simvastatin; Day 2: 0.25 mg digoxin; Day 7:20 mg simvastatin + 600 mg sodium bicarbonate; Day 8: 20 mg rosuvastatin; Day 10: 1000 mg acetaminophen; Day 12: 0.2 mg midazolam;Day 14: 1 mg Orforglipron, followed by 1000 mg acetaminophen administered 2 hours (±10 minutes) later (staggered); Day 15: 1 mg Orforglipron; Days 16-97: Orforglipron administered once daily with dose escalation every 14 days:1 mg (Days 16-27), 3 mg (Days 28-41),6 mg (Days 42-55),12 mg (Days 56-69),24 mg (Days 70-83),36 mg (Days 84-97).”

• See source wording

  by mouth · twice daily

  A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy ParticipantsPHASE1 · NCT06370728

  “Participants received study intervention through oral administration as follows: * Day 1: 1 milligram (mg) orforglipron capsule alone * Days 6 to 8: Twice daily (BID) doses of 100 mg carbamazepine tablets * Days 9 to 11: BID doses of 200 mg carbamazepine tablets * Days 12 to 14: BID doses of 300 mg carbamazepine tablets * Day 15: 1 mg orforglipron capsule co-administered with BID doses of 300 mg carbamazepine tablets * Days 16 to 18: BID doses of 300 mg carbamazepine tablets”

• 2.5 mg

  PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic ResponsesPHASE4 · NCT07739537

  “MMTT after 12 doses of orforglipron 2.5 mg.”

• See source wording

  by mouth · every 4 weeks · for 52 weeks

  A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 DiabetesPHASE3 · NCT06010004

  “3 mg Orforglipron.”

• See source wording

  by mouth · every 4 weeks

  A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity DiseasePHASE3 · NCT05931380

  “Treatment was initiated with placebo corresponding to 1 mg equivalent to Orforglipron, with dose escalation every 4 weeks to maintain blinding, and was continued through Week 72, unless dose interruption or modification was required.”